Efficacy of metformin combined with paclitaxel injection in the treatment of patients with endometrial carcinoma and its influence on tumor markers
10.3760/cma.j.cn115455-20240422-00353
- VernacularTitle:二甲双胍联合紫杉醇注射液治疗子宫内膜癌的疗效及对肿瘤标志物的影响
- Author:
Beibei WANG
1
;
Xiaojuan LI
;
Hong JIANG
Author Information
1. 陕西中医药大学附属医院妇科，咸阳 712000
- Keywords:
Endometrial neoplasms;
Metformin;
Paclitaxel;
Tumor markers;
Immunologic function
- From:
Chinese Journal of Postgraduates of Medicine
2024;47(12):1144-1148
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy of metformin combined with paclitaxel injection in the treatment of patients with endometrial carcinoma and the influence on tumor markers.Methods:Eighty patients with endometrial cancer admitted to the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2022 to June 2023 were retrospectively selected as the study objects, 40 of whom received chemotherapy with paclitaxel injection combined with carboplatin regimen (control group), and 40 received chemotherapy with metformin combined with paclitaxel injection and carboplatin regimen(observation group). The clinical efficacy, tumor markers, serum indicators and immune function indexes of the two groups were compared after 3 cycles of treatment.Results:After treatment, the total effective rate in the observation group was higher than that in the control group: 60.00%(24/40) vs. 37.50%(15/40), there was statistical difference ( χ2 = 4.05, P<0.05). After 3 cycles of treatment, the levels of human epididymal protein, cancer antigen 125, vascular endothelial growth factor, insulin-like growth factor 1 and hypoxia-inducible factor 1α in the observation group were lower than those in the control group: (27.05 ± 5.11) pmol/L vs. (33.96 ± 5.86) pmol/L, (24.11 ± 5.41) μg/L vs. (31.80 ± 5.53) μg/L, (215.68 ± 20.22) ng/L vs. (250.33 ± 20.19) ng/L, (170.33 ± 35.60) × 10 3 kU/L vs. (216.25 ± 41.72)×10 3 kU/L, (116.50 ± 20.17) ng/L vs. (147.77 ± 21.53) ng/L; the levels of glutathione peroxidase 1, cytotoxic T lymphocytes, natural killer cells and helper T lymphocytes in the observation group were higher than those in the control group: (271.63 ± 25.11) AU vs. (155.83 ± 22.60) AU, 0.25 ± 0.03 vs. 0.21 ± 0.02, 0.29 ± 0.03 vs. 0.23 ± 0.02, 0.41 ± 0.03 vs. 0.33 ± 0.04, there were statistical differences ( P<0.05). Conclusions:The combination of metformin, paclitaxel injection and carboplatin regimen in patients with endometrial cancer can improve the clinical efficacy, downregulate tumor marker expression, and improve serum oncological indicators, reducing immune damage.
